On March 13, China's National Medical Products Administration (NMPA) sent shock waves across the international medical technology sector by granting the world's first approval for an invasive, commercial-use brain-computer interface (BCI) system. Developed by Neuracle Medical Technology (Shanghai) Co. Ltd., the system restores hand movement for people with severe paralysis. The approval marks the beginning of a new era in which BCI technologies, long confined to laboratories and science fiction, break through into clinical medicine and begin treating medical issues at scale.

The coin-sized wireless implant used in Neuracle's system is surgically implanted onto the surface of the brain's outer membrane, where it picks up signals from the motor cortex, the brain area that controls movement. The implant decodes these signals and translates them into digital signals used to control robotic gloves, allowing users to perform basic hand functions.

Over the past two decades, the BCI technology has achieved astonishing successes in proof-of-concept experiments: Monkeys have used BCIs to control robotic arms to eat. Paralyzed people can use their minds to control cursors to type and operate robotic arms to drink. However, due to numerous obstacles such as safety, stability, long-term implant reliability and regulatory certification, before now, BCIs had not yet been transformed into medical products for widespread use.

The approval of Neuracle's system by the NMPA is the result of significant breakthroughs in a series of technological challenges in areas such as biocompatible materials, signal decoding algorithms, system integration, anti-interference ability, infection risk control, data security and privacy protection.

That the world's first invasive commercial-use BCI medical device was born in China is no coincidence. Behind this first lies the combined effect of multiple factors, including China's long-term investment in cutting-edge brain science, policy support for disruptive technology innovation and urgent market demand. During the 13th Five-Year Plan (2016-20) period, China began listing brain science and cybernetic brain research as a major national science and technology project and it continuously invested resources in this field. Shanghai, Beijing and Shenzhen have formed BCI innovation clusters covering basic research, materials science, integrated circuits, algorithm software and clinical medicine. Neuracle, a hi-tech enterprise incubated by Tsinghua University, is a typical representative of this innovative ecosystem.

The term BCI was included for the first time in this year's government work report, which was delivered by Premier Li Qiang to the annual session of the National People's Congress, the highest state organ of power, in March and outlines the government's priorities, together with quantum technology, embodied intelligence and 6G. It was also listed in the 15th Five-Year Plan (2026-30) as one of the emerging industries to be developed and strengthened over the next five years.

The clinical use of BCIs will bring unprecedented quality of life to people with severe disabilities. China has the world's largest group of people with nerve injuries. It is estimated that each year the number of new cases of spinal cord injury reaches the tens of thousands, and the number of people with limb dysfunction resulting from stroke is even larger. These people have an urgent need for functional reconstruction, providing a clinical foundation for the application of BCI technology. For these people, the access to BCIs restores not only function, but also dignity and independence.

Copyedited by G.P. Wilson 

Comments to lanxinzhen@cicgamericas.com